BR0013219A - Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto - Google Patents

Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto

Info

Publication number
BR0013219A
BR0013219A BR0013219-5A BR0013219A BR0013219A BR 0013219 A BR0013219 A BR 0013219A BR 0013219 A BR0013219 A BR 0013219A BR 0013219 A BR0013219 A BR 0013219A
Authority
BR
Brazil
Prior art keywords
treating
inhibiting
nsaid
kinase inhibitor
pharmaceutical composition
Prior art date
Application number
BR0013219-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Philip Frost
Carolyn Mary Discafani Marro
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR0013219A publication Critical patent/BR0013219A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0013219-5A 1999-08-12 2000-08-02 Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto BR0013219A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (1)

Publication Number Publication Date
BR0013219A true BR0013219A (pt) 2002-04-23

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013219-5A BR0013219A (pt) 1999-08-12 2000-08-02 Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto

Country Status (24)

Country Link
EP (1) EP1202746B1 (enExample)
JP (1) JP2003507342A (enExample)
KR (1) KR20020018201A (enExample)
CN (1) CN1229142C (enExample)
AR (1) AR029763A1 (enExample)
AT (1) ATE341341T1 (enExample)
AU (1) AU783116B2 (enExample)
BR (1) BR0013219A (enExample)
CA (1) CA2380904C (enExample)
CZ (1) CZ2002474A3 (enExample)
DE (1) DE60031127T2 (enExample)
DK (1) DK1202746T3 (enExample)
EA (1) EA006876B1 (enExample)
ES (1) ES2272305T3 (enExample)
HK (1) HK1042244A1 (enExample)
HU (1) HUP0203162A3 (enExample)
IL (1) IL147913A0 (enExample)
MX (1) MXPA02001448A (enExample)
NO (1) NO20020663L (enExample)
NZ (1) NZ517120A (enExample)
PL (1) PL353267A1 (enExample)
PT (1) PT1202746E (enExample)
WO (1) WO2001012227A1 (enExample)
ZA (1) ZA200201156B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
BR0109165A (pt) * 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
EP1409481B1 (en) 2001-07-16 2006-10-04 Astrazeneca AB Quinoline derivatives and their use as tyrosine kinase inhibitors
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1542989B1 (en) 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1551824B1 (en) 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
EP1758601A1 (en) 2004-06-03 2007-03-07 F.Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
RU2606114C2 (ru) * 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
EP1039910A1 (en) * 1997-11-06 2000-10-04 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Also Published As

Publication number Publication date
ES2272305T3 (es) 2007-05-01
CZ2002474A3 (cs) 2003-02-12
EA006876B1 (ru) 2006-04-28
AR029763A1 (es) 2003-07-16
PT1202746E (pt) 2007-01-31
NO20020663D0 (no) 2002-02-11
EP1202746B1 (en) 2006-10-04
AU6395900A (en) 2001-03-13
HUP0203162A2 (hu) 2003-01-28
HK1042244A1 (zh) 2002-08-09
NO20020663L (no) 2002-04-09
CA2380904C (en) 2009-02-10
IL147913A0 (en) 2002-08-14
EP1202746A1 (en) 2002-05-08
WO2001012227A1 (en) 2001-02-22
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
HUP0203162A3 (en) 2006-07-28
ZA200201156B (en) 2003-05-12
EA200200246A1 (ru) 2002-08-29
ATE341341T1 (de) 2006-10-15
KR20020018201A (ko) 2002-03-07
DK1202746T3 (da) 2007-01-02
PL353267A1 (en) 2003-11-03
CN1229142C (zh) 2005-11-30
DE60031127D1 (de) 2006-11-16
NZ517120A (en) 2004-10-29
CN1370080A (zh) 2002-09-18
JP2003507342A (ja) 2003-02-25
DE60031127T2 (de) 2007-02-01
MXPA02001448A (es) 2002-07-02

Similar Documents

Publication Publication Date Title
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
BR9916518A (pt) Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
BR9805544C1 (pt) Uso de um composto.
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
BRPI0415896A (pt) combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BR0213181A (pt) Combinações de inibidor de cox-2
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
BRPI0409473A (pt) combinação de um inibidor de cox-2 e um agente antineoplásico do tipo alquilante para o tratamento de neoplasia
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
BR0114856A (pt) Combinação compreendendo camptotecina e um derivado de estilbeno para o tratamento de câncer
BR0015121A (pt) Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação
BR0310027A (pt) Métodos de empregar uma combinação de uma 3-heteroaril-2-indolinona e um inibidor de ciclooxigenase-2 para o tratamento de neoplasia
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 45/06, A61K 31/505, A61K 31/47, A61P 35/00

Ipc: A61K 45/06 (2011.01), A61K 31/505 (2011.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.